Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Sienna Biopharmaceuticals Inc.’s lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker.
RedHill Biopharma reported positive safety and efficacy results from a late-stage clinical trial for the Israeli company’s treatment for Crohn’s disease called RHB-104.
Tonix Pharmaceuticals Inc. halted the company’s Phase III HONOR clinical trial of Tonmya (cyclobenzaprine HCL sublingual tablets) in military-related post-traumatic stress disorder.
Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.
The Mediterranean diet might do more than help ward off heart disease, it may also help improve psoriasis, a new study suggests.
Allergan and Molecular Partners’ drug for neovascular age-related macular degeneration met the main goal in two late-stage studies.
An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.
Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.
Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.
AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.
PainReform received FDA clearance to begin late-stage studies for a pain-relief drug that is a departure from opiate-based narcotics.
Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.
CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.
Japanese drugmaker Eisai Co. and Biogen Inc. said the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.
Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.
Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.
Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.
Britain’s Summit Therapeutics will stop developing the company’s Duchenne muscular dystrophy drug after ezutromid failed a mid-stage study, wiping out nearly 80 percent of its market value.